Cure Glomerulonephropathy (CureGN)
Number of Subjects in Study Archive: 2,400
Conditions: Glomerulonephritis, Glomerulosclerosis, Focal Segmental, Kidney Diseases
Duration: December 2014 - ongoing
# Recruitment Centers: 61
Available Genotype Data: No
Image Summary: No
Transplant Type: None
Does it have dialysis patients: No
Access to samples for Cure Glomerulonephropathy (CureGN) is currently only available via collaboration. Please contact the parent study to ask about ancillary study opportunities.
Glomerular diseases are chronic diseases that cause damage to the filters, glomeruli, in the kidneys. Damaged glomeruli allow red blood cells and protein to leak into the urine, cause waste products to build up in the blood, and can lead to kidney failure. Glomerular diseases affect individuals of all ages and tend to progress slowly in many patients. Due to lengthy follow-up periods and challenges with patient recruitment, previous efforts to study glomerular diseases have been difficult.
Cure Glomerulonephropathy Network (CureGN) is a multi-center consortium that seeks to establish an infrastructure for the advancement of glomerular disease studies. CureGN recruits and maintains a large and diverse population of glomerular disease patients. The study established a database of patients diagnosed with the following conditions: minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and immunoglobulin A nephropathy (IgAN).
Currently, data from one analysis dataset is available for request.
The objective of the CureGN study is to advance the diagnosis and care of patients with glomerular diseases.
Participants will undergo periodic assessments for disease progression; measure of kidney function; patient reported outcome measures; time to cause-specific events; and time to end stage kidney disease or death.
Participants of the study must be diagnosed with MCD, FSGS, MN, or IgAN via diagnostic kidney biopsy within 5 years of study enrollment. Additionally, participants must have access to the results and/or slides of their first kidney biopsy.
Individuals will be excluded from the study if they are an institutionalized patient; an organ or bone marrow transplant recipient; have end stage kidney disease; or have diagnosed cancer, Hepatitis B, Hepatitis C, HIV, diabetes mellitus, or systemic lupus erythematosus.
This study is ongoing.